{"id":"https://openalex.org/W2265751963","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","title":"Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray","display_name":"Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2265751963","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","mag":"2265751963"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.546","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111691704","display_name":"N. Berrada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"N. Berrada","raw_affiliation_strings":["Gustave Roussy Institute, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059010906","display_name":"Rosa Conforti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"R. Conforti","raw_affiliation_strings":["Gustave Roussy Institute, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083142899","display_name":"Suzette Delaloge","orcid":"https://orcid.org/0000-0003-2106-9165","observed_orcids":["https://orcid.org/0000-0003-2106-9165"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"S. Delaloge","raw_affiliation_strings":["Gustave Roussy Institute, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072115990","display_name":"M. Spielmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"M. Spielmann","raw_affiliation_strings":["Gustave Roussy Institute, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001814176","display_name":"Fabrice Andr\u00e9","orcid":"https://orcid.org/0000-0001-5795-8357","observed_orcids":["https://orcid.org/0000-0001-5795-8357","https://orcid.org/0000-0002-6272-6048"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"F. Andre","raw_affiliation_strings":["Gustave Roussy Institute, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Institute, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2801843802"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"546","last_page":"546"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11134","display_name":"Breast Lesions and Carcinomas","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8450000286102295},{"id":"https://openalex.org/keywords/molecular-classification","display_name":"molecular classification","score":0.6970000267028809},{"id":"https://openalex.org/keywords/p53-expression","display_name":"p53 expression","score":0.8420000076293945},{"id":"https://openalex.org/keywords/topoisomerase-iia","display_name":"topoisomerase IIa","score":0.7749999761581421},{"id":"https://openalex.org/keywords/adjuvant-chemotherapy","display_name":"adjuvant chemotherapy","score":0.7329999804496765},{"id":"https://openalex.org/keywords/basal-like-breast-cancer","display_name":"basal-like breast cancer","score":0.8610000014305115},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.734000027179718},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.48399999737739563},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.7059999704360962},{"id":"https://openalex.org/keywords/tissue-microarray","display_name":"tissue microarray","score":0.5730000138282776},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.4259999990463257},{"id":"https://openalex.org/keywords/ck5-6","display_name":"CK5/6","score":0.7919999957084656},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5879999995231628},{"id":"https://openalex.org/keywords/heterogeneity-test","display_name":"heterogeneity testing","score":0.48500001430511475},{"id":"https://openalex.org/keywords/interaction-testing","display_name":"interaction testing","score":0.4740000069141388}],"concepts":[{"id":"https://openalex.org/C193270364","wikidata":"https://www.wikidata.org/wiki/Q17141925","display_name":"Tissue microarray","level":3,"score":0.8074054718017578},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7529789805412292},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6652151942253113},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6607664823532104},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5978426933288574},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.56303471326828},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.5500185489654541},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5119191408157349},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4990999698638916},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4419122040271759},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44059547781944275},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4357627034187317},{"id":"https://openalex.org/C2778024521","wikidata":"https://www.wikidata.org/wiki/Q55639806","display_name":"Basal (medicine)","level":3,"score":0.42772141098976135},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3727990686893463},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20716145634651184},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.07081857323646545},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.0},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.546","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.546","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2339660864","https://openalex.org/W2263003589","https://openalex.org/W1989465474","https://openalex.org/W2117546979","https://openalex.org/W2118034665","https://openalex.org/W2052959548","https://openalex.org/W2025602971","https://openalex.org/W1998612051","https://openalex.org/W2050140049","https://openalex.org/W2142058321"],"abstract_inverted_index":{"546":[0],"Background:":[1],"Identification":[2],"of":[3],"highly":[4,54],"responsive":[5],"tumors":[6,31,52,73],"to":[7,14,56,298],"specific":[8],"regimen":[9,97,193],"is":[10],"needed":[11],"in":[12,181,211,244],"order":[13],"better":[15],"tailor":[16],"post-operative":[17],"chemotherapy":[18,37],"regimen.":[19,282],"We":[20],"previously":[21],"reported":[22,44],"using":[23,114],"a":[24,168,226,258],"tissue":[25,84],"microarrays":[26,85],"that":[27,45,137,270],"basal-like":[28,169,217],"and":[29,48,59,71,98,122,141,154,164,170,176,183,207,215,242,248,273,291],"HER2-overexpressing":[30,111,171],"derive":[32,74,276],"higher":[33],"benefit":[34,76,278],"from":[35,77,91,279],"adjuvant":[36,280],"than":[38],"luminal-like":[39],"tumors.":[40,110],"Previous":[41],"studies":[42],"have":[43,67],"p53+/basal-like":[46,70,214,271],"tumors,":[47],"HER2+/topoisomerase":[49],"IIa":[50,124,178],"+":[51],"were":[53,104,112,126,149,161,179,203,238],"sensitive":[55],"alkylating":[57],"agents":[58],"anthracyclines":[60],"respectively.":[61,174],"In":[62],"the":[63],"present":[64,267],"study,":[65],"we":[66],"evaluated":[68],"whether":[69],"HER2+TopIIa+":[72],"high":[75,277],"an":[78],"alkylating/anthracyclines":[79],"based":[80],"chemotherapy.":[81,100],"Methods:":[82],"A":[83,220,252],"was":[86,132,194,223,255],"built":[87],"with":[88,191,201,213,225,236,246,257],"tumor":[89],"samples":[90],"823":[92,159],"patients":[93,160,166,212,245],"randomized":[94],"between":[95],"FEC/FAC":[96,192,202,237,281],"no":[99],"Basal-like":[101],"breast":[102,172,218,250],"cancers":[103,275],"defined":[105,113],"as":[106],"HER2-/ER-/EGFR+":[107],"and/or":[108],"CK5/6+":[109],"HER2":[115],"expression":[116,125],"by":[117,128,134,151],"IHC":[118],"(3+":[119],"score).":[120],"P53":[121,175],"topoisomerase":[123,177],"assessed":[127,133,150],"IHC.":[129],"Treatment":[130],"effect":[131,148],"Cox":[135],"model":[136],"included":[138],"prognostic":[139],"parameters":[140],"stratification":[142],"variables.":[143],"Predictive":[144],"value":[145],"for":[146,156,188,228,260],"treatment":[147],"interaction":[152],"test":[153,155],"heterogeneity.":[157],"Results:":[158],"included.":[162],"12.5%":[163],"12.9%":[165],"presented":[167],"cancer":[173,272],"expressed":[180],"20%":[182],"35%":[184],"patients.":[185],"Hazard":[186,198,233],"ratio":[187,199,234],"relapse":[189],"associated":[190,200,224,235,256],"0.79":[195],"(95%CI:":[196],"0.62\u20131).":[197],"0.31":[204],"(0.1\u20130.97":[205],")":[206,210,241],"1.19":[208],"(0.38\u20133.7":[209],"p53-":[216],"cancer.":[219,251],"p53/basal-based":[221],"classification":[222,254],"trend":[227,259],"heterogeneity":[229,261],"(p":[230,262],"=":[231,263],"0.15).":[232],"0.34":[239],"(0.11\u20131.0":[240],"1.27(0.32\u20134.9)":[243],"topIIa+/HER2+":[247],"topIIa-/HER2+":[249],"HER2/TopIIa":[253],"0.07).":[264],"Conclusions:":[265],"The":[266],"study":[268],"suggest":[269],"TopIIA+/HER2":[274],"This":[283],"finding":[284],"requires":[285],"further":[286],"validation":[287],"given":[288],"multihypothesis":[289],"testing":[290],"subgroup":[292],"analysis.":[293],"No":[294],"significant":[295],"financial":[296],"relationships":[297],"disclose.":[299]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-07T09:51:55.459714","created_date":"2016-06-24T00:00:00"}